Carmelo Scarpignato (C Scarpignato)

Loop profile ORCID

Publication Activity (10 Years)

Years Active: 2017-2024
Publications (10 Years): 23

Top Venues

Alimentary pharmacology & therapeutics

Therapeutic advances in gastroenterology

Annals of the New York Academy of Sciences

Biomedicines

University of Parma

This page only lists publications with an associated author ORCID identifier.

Affiliation History

University of Parma Nov 01 1985

Italy

Professor of Clinical Pharmacology :: Department of Medicine

Publications

Peter J Whorwell, Robert Lange, Carmelo Scarpignato
Review article: do stimulant laxatives damage the gut? A critical analysis of current knowledge. Therapeutic advances in gastroenterology 17 (2024)
Carmelo Scarpignato, Richard H Hunt
Potassium-competitive Acid Blockers: Current Clinical Use and Future Developments. Current gastroenterology reports (2024)
Lara M Ruiz-Belmonte, Patricia Carrera-Lasfuentes, Alberto Cebollada, Carmelo Scarpignato, Angel Lanas, Carla Jerusalén Gargallo-Puyuelo
Predictive Score for Advanced Colorectal Neoplasia Based on Cardiovascular and Colorectal Cancer Risk Factors. Journal of clinical medicine 13 (10) (2024)
Lara M Ruiz-Belmonte, Patricia Carrera-Lasfuentes, Alberto Cebollada, Carmelo Scarpignato, Angel Lanas, Carla Jerusalén Gargallo-Puyuelo
Predictive Score for Advanced Colorectal Neoplasia Based on Cardiovascular and Colorectal Cancer Risk Factors. Journal of clinical medicine 13 (10) (2024)
Angela Tietto, Sofia Faggin, Carmelo Scarpignato, Edoardo Vincenzo Savarino, Maria Cecilia Giron
Safety of potassium-competitive acid blockers in the treatment of gastroesophageal reflux disease. Expert opinion on drug metabolism & toxicology (2024)
Luigi Gatta, Massimo Bellini, Carmelo Scarpignato, Walter Marrocco, Alberto Chiriatti, Antonio Grosso, Christian Lambiase, Paolo Usai-Satta, Roberto Vassallo, Pierluigi Bartoletti, Fabio Monica, Raffaele Manta, Silvestro Scotti, Marco Soncini, null null
Rifaximin in diverticulosis and diverticular disease: a national survey among Italian gastroenterologists and general practitioners. Internal and emergency medicine (2024)
Peter J Whorwell, Robert Lange, Carmelo Scarpignato
Review article: do stimulant laxatives damage the gut? A critical analysis of current knowledge. Therapeutic advances in gastroenterology 17 (2024)
Carmelo Scarpignato, Colin W Howden, Eckhard Leifke, Darcy J Mulford, Gezim Lahu, Axel Facius, Richard H Hunt
A translational pharmacokinetic/pharmacodynamic approach supports optimal vonoprazan dosing for erosive oesophagitis and Helicobacter pylori infection. Alimentary pharmacology & therapeutics (2023)
Valentina Urzì Brancati, Carmelo Scarpignato, Letteria Minutoli, Giovanni Pallio
Use of Pharmacogenetics to Optimize Immunosuppressant Therapy in Kidney-Transplanted Patients. Biomedicines 10 (8) (2022)
Claudio Romano, Carmelo Scarpignato
Pharmacologic treatment of GERD in adolescents: Is esophageal mucosal protection an option? Therapeutic advances in gastroenterology 15 (2022)
Carmelo Scarpignato, Richard H Hunt
Editorial: acid suppression with potassium-competitive acid blockers dismissing genotype concerns. Alimentary pharmacology & therapeutics 53 (1) (2021)
Issac E Perry, Irene Sonu, Carmelo Scarpignato, Junichi Akiyama, Michio Hongo, Kenneth J Vega
Potential proton pump inhibitor-related adverse effects. Annals of the New York Academy of Sciences 1481 (1) (2020)
Carmelo Scarpignato, Joshua A Sloan, David H Wang, Richard H Hunt
Gastrointestinal pharmacology: practical tips for the esophagologist. Annals of the New York Academy of Sciences 1481 (1) (2020)
Nielsen Q Fernandez-Becker, Shreya Raja, Carmelo Scarpignato, Kristle L Lynch, Nitin K Ahuja, Jennifer L Horsley-Silva
Eosinophilic esophagitis: updates on key unanswered questions. Annals of the New York Academy of Sciences 1481 (1) (2020)
Carmelo Scarpignato, Richard H Hunt
Editorial: potassium-competitive acid blockers for acid-related diseases-tegoprazan, a new kid on the block. Alimentary pharmacology & therapeutics 50 (8) (2020)
Giovanni Pallio, Alessandra Bitto, Antonio Ieni, Natasha Irrera, Federica Mannino, Socrate Pallio, Domenica Altavilla, Francesco Squadrito, Carmelo Scarpignato, Letteria Minutoli
Combined Treatment with Polynucleotides and Hyaluronic Acid Improves Tissue Repair in Experimental Colitis. Biomedicines 8 (10) (2020)
Carmelo Scarpignato, Ingvar Bjarnason
Drug-Induced Small Bowel Injury: a Challenging and Often Forgotten Clinical Condition. Current gastroenterology reports 21 (11) (2019)
Luigi Gatta, Carmelo Scarpignato
Editorial: Helicobacter pylori resistance and sequential therapy-authors' reply. Alimentary pharmacology & therapeutics 48 (1) (2019)
Carmelo Scarpignato, Corrado Blandizzi
Letter: can the overall gastrointestinal safety of celecoxib be extended to all COX-2-selective agents? Alimentary pharmacology & therapeutics 48 (1) (2019)
Luigi Gatta, Carmelo Scarpignato, G Fiorini, J Belsey, I M Saracino, C Ricci, D Vaira
Impact of primary antibiotic resistance on the effectiveness of sequential therapy for Helicobacter pylori infection: lessons from a 5-year study on a large number of strains. Alimentary pharmacology & therapeutics 47 (9) (2018)
Carmelo Scarpignato, Giovanni Barbara, Angel Lanas, Lisa L Strate
Management of colonic diverticular disease in the third millennium: Highlights from a symposium held during the United European Gastroenterology Week 2017. Therapeutic advances in gastroenterology 11 (2018)
Luigi Gatta, Carmelo Scarpignato
Systematic review with meta-analysis: rifaximin is effective and safe for the treatment of small intestine bacterial overgrowth. Alimentary pharmacology & therapeutics 45 (5) (2017)
V Savarino, F Pace, Carmelo Scarpignato, null null
Randomised clinical trial: mucosal protection combined with acid suppression in the treatment of non-erosive reflux disease - efficacy of Esoxx, a hyaluronic acid-chondroitin sulphate based bioadhesive formulation. Alimentary pharmacology & therapeutics 45 (5) (2017)

Carmelo Scarpignato.css-eqlu8i{font-size:small;padding-left:4px;} (C Scarpignato)

Publication Activity (10 Years)

Top Topics

Top Venues

Carmelo Scarpignato (C Scarpignato)